Al­lo­gene hit with FDA clin­i­cal hold af­ter a pa­tient ex­pe­ri­ences 'ab­nor­mal­i­ty' in CAR-T cells — shares ham­mered

The FDA has slapped a clin­i­cal hold on Al­lo­gene’s clin­i­cal tri­als af­ter a pa­tient in one of their ear­ly-stage stud­ies for the off-the-shelf cell ther­a­py AL­LO-501A de­vel­oped a “chro­mo­so­mal ab­nor­mal­i­ty” in their CAR-T cells.

The biotech $AL­LO re­port­ed af­ter the mar­ket close on Thurs­day that ex­ec­u­tives plan to fol­low up in the com­ing weeks with reg­u­la­tors as the FDA con­sid­ers the biotech’s plan to take this drug in­to a piv­otal tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER